Akebia Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

AKBA$0.54+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

	Three Months Ended March 31,
(dollars in thousands, except per share amounts)	2026	2025
Revenues
Product revenue, net	$51,992	$55,791
License, collaboration and other revenue	1,552	1,545
Total revenues	53,544	57,336
Cost of goods sold
Cost of product and other revenue	12,290	7,625
Total cost of goods sold	12,290	7,625
Operating expenses:
Research and development	14,807	9,754
Selling, general and administrative	30,436	25,742
License	707	701
Total operating expenses	45,950	36,197
Income (loss) from operations	(4,696)	13,514
Other income (expense)
Interest expense	(4,691)	(7,770)
Other income	3	213
Change in fair value of warrant liability	456	155
Income (loss) before income taxes	(8,928)	6,112
Income tax expense	(126)	—
Net income (loss)	$(9,054)	$6,112
Comprehensive income (loss)	$(9,054)	$6,112
Net income (loss) per share:
Basic	$(0.03)	$0.03
Diluted	$(0.03)	$0.03
Weighted average shares of common stock outstanding:
Basic	267,046,755	235,497,720
Diluted	267,046,755	241,602,853

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.